Syncom Formulations (India) Limited (SYNCOMF.NS)

INR 21.04

(-0.14%)

Market Cap (In INR)

19.77 Billion

Revenue (In INR)

2.59 Billion

Net Income (In INR)

253.14 Million

Avg. Volume

13.76 Million

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
10.55-27.9
PE
-
EPS
-
Beta Value
1.495
ISIN
INE312C01025
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Kedarmal Shankarlal Bankda M.Com
Employee Count
-
Website
https://www.syncomformulations.com
Ipo Date
2022-11-18
Details
Syncom Formulations (India) Limited manufactures, markets, and sells pharmaceutical formulation products in India. It offers various products, including generics, alpha adrenoceptor agonists, analgesics, antipyretics, anti-inflammatory, anti-ulcer agents, antibiotics, antidepressants, antifungals, antihistamines, antimalarial, antiplatelet agents, antiprotozoal, antivirals, bronchodilators, calcium antagonists, cardiac medicines, central nervous stimulants, cephelo sporins, cortico steroids, estrogen, cough suppressants, erectile dysfunction, and electrolite. The company also provides histamines, homeostatic, hypoglycemic, hypolipidaemics, local anesthetics, multivitamins and nutritional supplements, sedative anticonvulsants, stimulants, and sympathomimetic products, as well as products used in the treatment of gout. In addition, it engages in the trading of commodities and renting of properties. Further, the company exports its products. It offers its pharmaceutical formulations products in various dosage forms, such as tablets, capsules, liquids orals, liquid vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and herbals. Syncom Formulations (India) Limited was founded in 1985 and is based in Indore, India.